Literature DB >> 1105533

Oral bumetanide in chronic renal failure.

M E Allison, M K Lindsay, A C Kennedy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1105533

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  6 in total

1.  Assessment of natriuretic drugs.

Authors:  C J Roberts; T K Daneshmend
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

2.  Bumetanide and frusemide: a comparison of dose-response curves in healthy men.

Authors:  L E Ramsay; G T McInnes; J Hettiarachchi; J Shelton; P Scott
Journal:  Br J Clin Pharmacol       Date:  1978-03       Impact factor: 4.335

3.  Oral piretanide in chronic renal failure.

Authors:  I S Henderson; T J Beattie; A C Kennedy; S L Dombey
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

4.  The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.

Authors:  L A Marcantonio; W H Auld; W R Murdoch; R Purohit; G G Skellern; C A Howes
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

Review 5.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

6.  Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.

Authors:  Fabio Solis-Jimenez; Lucia Monserrat Perez-Navarro; Ricardo Cabrera-Barron; Jesus Antonio Chida-Romero; Geovana Martin-Alemañy; Edgar Dehesa-López; Magdalena Madero; Rafael Valdez-Ortiz
Journal:  BMC Nephrol       Date:  2022-09-20       Impact factor: 2.585

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.